Beyond the Cure: The Children’s Oncology Group’s Efforts to Improve Outcomes for Pediatric Cancer Patients Long after Treatment has Finished (C223)

3:15 – 4:15 pm Friday, September 14

coglogo1CNE  Childhood cancer survivors are living longer than ever before, with overall survival rates exceeding 80%. As a result, survivors also are living with chronic late health effects related to their curative treatments, with 40% of survivors experiencing a severe, disabling, and life-threatening or fatal late effect at 30 years post-treatment. Late effects may include second malignancies, endocrinopathies, cardiomyopathy, infertility, pulmonary function deficits, renal/ocular/auditory disorders, neurocognitive deficits, and metabolic syndrome. Recent studies report that cumulative incidence of late effects may be even higher than previously reported, with survivors having 3 to 5 treatment-related chronic health conditions by the age of 50.

This evidence makes it clear that survivors need specific education regarding their unique risk for late effects. Early detection through screening and prompt intervention and treatment is vital in order to minimize the burden of late effects which can negatively impact the survivor’s quality of life. Substantial data regarding the late effects of traditional chemotherapy and radiotherapy is now available, yet little is known about the long-term risks of more modern therapies, including precision medicine and targeted treatments such as immunotherapy and antibody therapy. This session will use survivor-specific exemplars to examine treatment-related exposures and potential subsequent late effects. The newly updated Children’s Oncology Group (COG) Long-Term Follow Up Guidelines will direct these surveillance recommendations. Finally, the most recent long-term follow up study from the COG, ALTE15N2 – Late Effects After High Risk Neuroblastoma (LEARHN), will be highlighted, as this is among the first studies aiming to understand more about contemporary treatments, on the background of intensive chemotherapy, radiotherapy, and transplant.